Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 2/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11668776 | 0.93 | MEN1 (0.54) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL20937014 | 0.91 | LTA4H (0.54) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL8632462 | 0.91 | CYP1A2 (0.55) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL9830045 | 0.91 | MEN1 (0.52) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL23583339 | 0.89 | CYP1A2 (0.59) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL11585949 | 0.89 | KDM5A (0.53) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL3903055 | 0.88 | DNM1 (0.50) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL3902356 | 0.88 | MEN1 (0.48) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL4437145 | 0.88 | KDM5A (0.59) | MEN1KMT2ACYP1A2LTA4HALDH1A1 | |
| SCHEMBL11585402 | 0.86 | KDM5A (0.60) | MEN1KMT2ACYP1A2LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207744-A1 | DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA | EXPANSION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200207744-A1 | DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA | EXPANSION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-8003621-B2 | Drug carriers | NITTO DENKO CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090105179-A1 | DRUG CARRIERS | NITTO DENKO CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2008141057-A1 | DEUTERATED PIMAVANSERIN 1- (4-FLU0R0BENZYL) -3- (4-ISOBUTOXYBENZYL) -1- ( L-METHYL-PIPERIDIN-4-YL) -UREA | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280886-A1 | SUBSTITUTED UREAS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207744-A1 | DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA | HNRNPH1, HNRNPUL2, HNRNPH3 | MEN1 1977/4885KMT2A 900/4885GAA 1486/4885 |
| US-20090105179-A1 | DRUG CARRIERS | HDGF, FIBP, SLC47A2 | MEN1 2244/4885KMT2A 4715/4885GAA 634/4885 |
| US-20080280886-A1 | SUBSTITUTED UREAS | HTR4, HTR5A, HTR6 | MEN1 4078/4885KMT2A 2286/4885GAA 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.